Skip to content
Molecules
SEKISUI XenoTech DD Blog Logo

Drug Development Blog

Commentary to provide context and explain significance of research is sometimes just as important as the research itself. That’s why our experts make it a priority to provide you with helpful content distilled from the many years of experience our team has accumulated. The Drug Development Insights blog contains overviews and deep dives into the drug metabolism and pharmacokinetics topics you care about—regulatory expectations, risk assessment, safety considerations, scientific innovation, study design elements, interpretation of results, and more. Explore our entries chronologically or by category to get insight into the many pieces of your drug’s development.

Meet the Scientists: Program Execution

In this installment of our Meet the Scientist series, we asked several members from various areas of our Program Execution...

Interesting Topics at the 3rd SCI-RSC Symposium on Transporters in Drug Discovery and Development

Several members of the SEKISUI XenoTech team had the pleasure of attending the virtual Symposium on Transporters in Drug Discovery...

Meet the Scientists: Analytical Services’ Chandra Kollu & Nadya Galeva

This month we’re featuring two of the experts in our analytical services department: Senior Scientist Chandra Kollu and Mass Spectrometry...

ADME/PK & DDI Best Practices Industry Survey Results & Infographic

We recently ran an industry survey to help us understand what the current industry standards are for when and why...

Guide to When & Why to Evaluate ADME/DMPK & Drug-Drug Interactions Available

In Safety first: Assessing drugs early can preclude regulatory and health issues, a new ebook developed by a collaboration with...

Meet the Scientist: Darina Hynes

Dr. Darina Hynes obtained her Ph.D. in Molecular Medicine from the Royal College of Surgeons in Ireland. She is currently a...

Why Switch to Hepatocyte Pellets?

You may have heard about the patented CryostaX® format of hepatocyte pellets, but do you know why SEKISUI XenoTech and countless other researchers have made…

Meet the Scientist: Shanté Jackson

Shanté is a Research Scientist who joined SXT in 2017 and serves as a Drug Inhibition and Drug Metabolism Study Director and Drug Transport Lead…

Four Ways CROs Drive Innovation for Improved In Vitro Drug Metabolism and Pharmacokinetics (DMPK) Studies

Agility and focused growth allow drug developers to outsource expertise and benefit the industry at-large by fostering innovation. Panelists at the 2021 Annual DMDG Meeting…

DDI & Drug Repurposing Article featured in Drug Discovery World (DDW) Spring Edition 2021

Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success.…

Improve the Value of Your Molecule's Testing with Expert Insight

Our expert team of DDI and drug metabolism consultants can help you piece together the data for a successful data package that meets regulatory expectations for thorough risk assessment of a new or repurposed compound

Read our Follow-Up Interview in Outsourcing Pharma

Find the Q&A between Director of Scientific Consulting, Dr. Maciej Czerwinski, and the editorial team at Outsourcing Pharma for more answers about how DDI testing and data interpretation adds value to the drug repurposing process

Human antibodies, including monoclonal and polyclonal, are used for inhibition and immunoblot applications